EMA acts to impose some sort of order on secondary data analysis
This article was originally published in Scrip
The European Medicines Agency concedes it will not be able to police all secondary data analyses undertaken by independent researchers once it grants them access to raw clinical trial data submitted in support of EU drug applications.
You may also be interested in...
The European Medicines Agency is developing a strategy to ensure that women have sufficient information to make informed choices about taking medicines during pregnancy and breastfeeding.
A first-of-its-kind collaborative study has found that real-world and natural history data are comparable to placebo data from clinical trials in Duchenne muscular dystrophy.
An EU group has listed several ambitious projects to help EU regulators realize their cherished vision of using big data capabilities to support innovation and public health. But these proposals may take a backseat as COVID-19-related challenges continue.